Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

GM-CSF Protein

Dieses Recombinant GM-CSF-Protein wird in HEK-293 Cells exprimiert.
Produktnummer ABIN7318085

Kurzübersicht für GM-CSF Protein (ABIN7318085)

Target

Alle GM-CSF (CSF2) Proteine anzeigen
GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Protein-Typ

Recombinant

Biologische Aktivität

Active

Spezies

  • 31
  • 14
  • 12
  • 5
  • 4
  • 3
  • 2
  • 1
  • 1
  • 1
  • 1
Human

Quelle

  • 36
  • 8
  • 8
  • 5
  • 5
  • 4
  • 3
  • 1
  • 1
  • 1
HEK-293 Cells

Reinheit

> 90 % as determined by reducing SDS-PAGE.
  • Verwendungszweck

    Recombinant Human GM-CSF/CSF2 Protein (HEK293 Cells)(Active)

    Sequenz

    Met 1-Glu144

    Produktmerkmale

    A DNA sequence encoding human GMCSF (NP_000749.2) (Met1-Glu144) was expressed.

    Endotoxin-Niveau

    < 1.0 EU per μg as determined by the LAL method.

    Biological Activity Comment

    Measured in a cell proliferation assay using TF-1 human erythroleukemic cells.The ED50 for this effect is typically 0.1-0.6 ng/ml.
  • Möchten Sie weitere Optionen für dieses Protein ?

    !
    Entdecken Sie unsere vordefinierten maßgeschneiderten Proteine und Proteinservices!

    Ihr Projekt erfordert weitere Anpassungen? Kontaktieren Sie uns und entdecken Sie unsere maßgeschneiderten Proteinlösungen

  • Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Please refer to the printed manual for detailed information.

    Buffer

    Lyophilized from sterile PBS, pH 7.4. 1. Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. 2. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hard copy of CoA.

    Lagerung

    4 °C,-20 °C,-80 °C

    Informationen zur Lagerung

    Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
  • Target

    GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

    Andere Bezeichnung

    GM-CSF/CSF2

    Hintergrund

    Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

    Synonym: Granulocyte-Macrophage Colony-Stimulating Factor; GM-CSF; Colony-Stimulating Factor; CSF; Molgramostin; Sargramostim; CSF2; GMCSF

    Molekulargewicht

    14.5 kDa

    NCBI Accession

    NP_000749

    Pathways

    JAK-STAT Signalweg, Cellular Response to Molecule of Bacterial Origin
Sie sind hier:
Chat with us!